Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in Metastatic Renal Cell Carcinoma (mRCC) Patients

NCT02324803 is registered in ClinicalTrials.gov with Southern China Urology Cancer Consortium as lead sponsor.

NCT NCT02324803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02324803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in Metastatic Renal Cell Carcinoma (mRCC) Patients
Lead sponsor
Southern China Urology Cancer Consortium
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2014
Completion date
December 31, 2015
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug event, carcinoma, renal cell, self efficacy